HIV Entry Inhibitors and Their Potential in HIV Therapy

被引：99

作者：

Qian, Keduo ^{[1
]}

Morris-Natschke, Susan L. ^{[1
]}

Lee, Kuo-Hsiung ^{[1
]}

机构：

[1] Univ N Carolina, Sch Pharm, Nat Prod Res Labs, Chapel Hill, NC 27599 USA

来源：

MEDICINAL RESEARCH REVIEWS | 2009年 / 29卷 / 02期

关键词：

HIV entry inhibitors; attachment inhibitors; co-receptor binding inhibitors; fusion inhibitors; maraviroc (MVC; UK-427,857); enfuvirtide (T20; fuzeon); bevirimat (DSB; PA-457); HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR CXCR4; SMALL-MOLECULE INHIBITOR; ANTI-AIDS AGENTS; BETULINIC ACID-DERIVATIVES; DOWN-MODULATING COMPOUNDS; HUMAN CCR5 RECEPTOR; ANTIRETROVIRAL THERAPY; CONFORMATIONAL-CHANGES; ENVELOPE GLYCOPROTEIN;

D O I：

10.1002/med.20138

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

This review discusses recent progress in the development of anti-HIV agents targeting the viral entry process. The three main classes (attachment inhibitors, co-receptor binding inhibitors, and fusion inhibitors) Lire further broken clown by specific mechanism of action and structure. Many of these inhibitors are in advanced clinical trials, including the HIV Maturation inhibitor bevirimat, from the authors' laboratories. In addition, the CCR5 inhibitor maraviroc has recently been FDA-approved. Possible roles for these agents in anti-HIV therapy, including treatment of virus resistant to current drugs, are also discussed. (C) 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 2, 369-393, 2009

引用

页码：369 / 393

页数：25

共 147 条

[1] EXPRESSION AND CHARACTERIZATION OF CD4-IGG(2), A NOVEL HETEROTETRAMER THAT NEUTRALIZES PRIMARY HIV TYPE-1 ISOLATES [J].

ALLAWAY, GP ;

DAVISBRUNO, KL ;

BEAUDRY, GA ;

GARCIA, EB ;

WONG, EL ;

RYDER, AM ;

HASEL, KW ;

GAUDUIN, MC ;

KOUP, RA ;

MCDOUGAL, JS ;

MADDON, PJ .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (05) :533-539

[2] T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure [J].

Arakaki, R ;

Tamamura, H ;

Premanathan, M ;

Kanbara, K ;

Ramanan, S ;

Mochizuki, K ;

Baba, M ;

Fujii, N ;

Nakashima, H .

JOURNAL OF VIROLOGY, 1999, 73 (02) :1719-1723

[3] The anti-HIV activity of ADS-J1 targets the HIV-1 gp120 [J].

Armand-Ugón, M ;

Clotet-Codina, I ;

Tintori, C ;

Manetti, F ;

Clotet, B ;

Botta, M ;

Esté, JA .

VIROLOGY, 2005, 343 (01) :141-149

[4] The discovery of CCR5 receptor antagonists for the treatment of HIV infection: Hit-to-lead studies [J].

Armour, Duncan ;

de Groot, Marcel J. ;

Edwards, Martin ;

Perros, Manos ;

Price, David A. ;

Stammen, Blanda L. ;

Wood, Anthony .

CHEMMEDCHEM, 2006, 1 (07) :706-+

[5] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].

Baba, M ;

Nishimura, O ;

Kanzaki, N ;

Okamoto, M ;

Sawada, H ;

Iizawa, Y ;

Shiraishi, M ;

Aramaki, Y ;

Okonogi, K ;

Ogawa, Y ;

Meguro, K ;

Fujino, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703

[6] Highly active antiretroviral therapy: Current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome [J].

Barbaro, G ;

Scozzafava, A ;

Mastrolorenzo, A ;

Supuran, CT .

CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (14) :1805-1843

[7] Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues [J].

Bell, TW ;

Anugu, S ;

Bailey, P ;

Catalano, V ;

Dey, K ;

Drew, MGB ;

Duffy, NH ;

Jin, Q ;

Samala, MF ;

Sodoma, A ;

Welch, WH ;

Schols, D ;

Vermeire, K .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (04) :1291-1312

[8] Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J].

Berger, EA ;

Murphy, PM ;

Farber, JM .

ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :657-700

[9] A new classification for HIV-1 [J].

Berger, EA ;

Doms, RW ;

Fenyö, EM ;

Korber, BTM ;

Littman, DR ;

Moore, JP ;

Sattentau, QJ ;

Schuitemaker, H ;

Sodroski, J ;

Weiss, RA .

NATURE, 1998, 391 (6664) :240-240

[10] The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis [J].

Blanco, J ;

Barretina, J ;

Henson, G ;

Bridger, G ;

De Clercq, E ;

Clotet, B ;

Esté, JA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :51-56

← 1 2 3 4 5 6 7 8 9 10 →